Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 3:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 102 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Amblyopia
Interventions
Eye patch, spectacles, atropine
Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 17 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Budesonide, budesonide/formoterol, Ipratropium/albuterol
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
45 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
7
States / cities
Birmingham, Alabama • Torrance, California • Denver, Colorado + 4 more
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Inhaled Atropine Sulfate in Healthy Adults

NCT00947596
Conditions
Organophosphorus Poisoning
Interventions
atropine sulfate
Drug
Lead sponsor
MicroDose Defense Products L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Formoterol Fumurate inhalation solution 20 mcg, Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
San Diego, California • Denver, Colorado • Wheat Ridge, Colorado + 12 more
Conditions
Chest Pain, Angina, Angina Pectoris, Coronary Artery Disease
Interventions
Stress Echocardiography, Coronary CT Angiography
Procedure
Lead sponsor
Montefiore Medical Center
Other
Eligibility
30 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Not yet recruiting Phase 2 Interventional

Effect of Ipratropium Bromide on EILO

NCT07394036
Conditions
Exercise-Induced Laryngeal Obstruction, Dyspnea During Activity
Interventions
Ipratropium Bromide, Normal Saline (Placebo)
Drug
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
8 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Prosper, Texas
Conditions
Solid Tumors, Lymphoma
Interventions
LMP744, Ondansetron, Olanzapine, Lorazepam, Diphenoxylate hydrocholoride (HCL) + Atropine Sulfate, Loperamide, Diphenhydramine, Steroid, Epinephrine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Bethesda, Maryland • Pittsburgh, Pennsylvania
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Albuterol/salbutamol, Ipratropium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Conditions
Accomodation, Biofeedback Training, Myopia
Interventions
Auditory biofeedback traing
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
8 Years to 15 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Long Beach, New York
Conditions
Asthma
Interventions
ipratropium
Drug
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 2 Interventional Results available

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

NCT01391962
Conditions
Sarcoma, Alveolar Soft Part
Interventions
Cediranib, Sunitinib, Prochlorperazine, Promethazine, Benzodiazepine, Filgrastim, Sargramostim, Lomotil, Loperamide, Vitamin B6, Aquaphor, Acetaminophen, Levothyroxine, Warfarin
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years to 120 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Atropine, Exercise treadmill test
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Non-small Cell Lung Cancer
Interventions
Irinotecan
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Endotracheal intubation, Laryngeal mask airway, remifentanil
Device · Drug
Lead sponsor
Albany Medical College
Other
Eligibility
2 Hours to 48 Hours
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Albany, New York
Conditions
COPD, Acute Respiratory Failure
Interventions
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Changes in Eye Shape With Myopia Management Interventions

NCT06450132
Conditions
Myopia
Interventions
Atropine Ophthalmic, MiSight 1-day disposable contact lenses
Drug · Device
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 30 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
1 Day to 2 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more
Conditions
Myopia
Interventions
Atropine, MiSight contact lenses
Drug · Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
5 Years to 12 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Response to Atropine Drops (RAD) Study

NCT05199597
Conditions
Myopia
Interventions
0.01% atropine, 0.05% atropine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Asthma
Interventions
Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
41
States / cities
Birmingham, Alabama • Los Angeles, California • Palmdale, California + 36 more
Conditions
Amblyopia
Interventions
Atropine, Eye Patch
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Asthma, Acute Asthma, Reactive Airway Exacerbation
Interventions
Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg, Prednisolone, prednisone, or methylprednisolone, Albuterol, ipratropium bromide, Ipratropium bromide
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Myopia
Interventions
Atropine 0.01% Ophthalmic Solution, Atropine 0.02% Ophthalmic Solution, Atropine 0.05% Ophthalmic Solution
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Berkeley, California